Catalent (CTLT) : Fridays money flow points at investors jumping to buy the stock on the weakness of price. $0.45 million worth of transactions were on upticks, whereas, the downticks accounted for $0.16 million worth of transactions. The net money flow was a positive $0.29 million and the uptick to downtick ratio was 2.89. The net money flow into the stock was $0.37 million. The lack of interest in trading on downticks shows that the investors dont want to sell their holdings. The upticks accounted for $0.37 million of the total block trades, indicating continued buying interest on weakness, which bodes well for the future of the stock. Catalent (CTLT) was trading at $25.21, down $0.03 during day. The stock slid -0.1% over the previous days close. For the week, the stock recorded 0.82% over the previous weeks close.
The company Insiders own 0.98% of Catalent shares according to the proxy statements. Institutional Investors own 99.72% of Catalent shares.
In a related news, Walsh Matthew M, officer (See Remarks) of Catalent, Inc., unloaded 21,197 shares at an average price of $28.85 on May 27, 2016. The total amount of the transaction was worth $611,533, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Catalent (NYSE:CTLT): The stock opened at $25.48 and touched an intraday high of $25.61 on Friday. During the day, the stock corrected to an intraday low of $25.03, however, the bulls stepped in and pushed the price higher to close in the green at $25.24 with a gain of 0.04% for the day. The total traded volume for the day was 690,826. The stock had closed at $25.23 in the previous trading session.
Catalent (CTLT) has been under a strong bear grip, hence the stock is down -0.22% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.45% in the past 1 week. The stock has risen by 0.96% in the past week indicating that the buyers are active at lower levels, but the stock is down -0.36% in the past 4 weeks.
Catalent, Inc. is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Companys segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecules lifecycle. The Medication Delivery Solutions segment provides formulation, development and manufacturing services for delivery of drugs and biologics, administered through injection, inhalation and ophthalmic routes, using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing, packaging, storage and inventory management for drugs and biologics in clinical trials.